Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2–Positive Patients: A Nationwide Cohort Study From the Czech Republic

Tomáš Pavlík, Jiří Jarkovský, Ondřej Šanca, Martina Koziar Vašáková, Pavel Dlouhý, Vladimír Černý, Petr Štourač, Vlastimil Válek, Ladislav Dušek · 2024

Read Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2–Positive Patients: A Nationwide Cohort Study From the Czech Republic by Tomáš Pavlík, Jiří Jarkovský, Ondřej Šanca, Martina Koziar Vašáková, Pavel Dlouhý, Vladimír Černý, Petr Štourač, Vlastimil Válek, Ladislav Dušek (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11630851.txt.

Description

Tomas Pavlik and co-authors present a 2024 study on a covid drug in the Czech Republic. The drug, molnupiravir, was tested in a nationwide group during the Omicron wave. All 74,541 adults with a recorded infection in 2022 who got the drug were analyzed. Death within thirty days was the main outcome, with covid-linked death as a second one.

Use of the drug tied to a much lower risk of death by either measure. Adjusted risk was cut by about two-fifths for all deaths and by half for covid deaths. The link held across sex, health burden, hospital status, and vaccine status. It also held for patients over sixty-five. The authors back early use of the drug.

Catalog record

CREATORTomáš Pavlík, Jiří Jarkovský, Ondřej Šanca, Martina Koziar Vašáková, Pavel Dlouhý, Vladimír Černý, Petr Štourač, Vlastimil Válek, Ladislav Dušek
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11630851

Browse the full library · About the Tower of Babel